Platform of Science & Expertise

Preclinical Services

MD Biosciences AAALAC accredited Preclinical Services Laboratories provide exclusive, in-depth studies in the core areas of immunology, inflammatory diseases and neurology. Therapeutic areas include cancer, with particular focus on onco-immunology, joint, respiratory, gastrointestinal and skin inflammation, wound healing and metabolic studies. Pain and neurodegenerative diseases form the core of our strong CNS and neurological studies area. Studies are accompanied by a host of in vitro methodologies including multiplex protein analysis, qPCR, flow cytometry, histology and immunohistochemistry, offering the opportunity to investigate mode of action of candidate drugs.

Discover

CLIA Clinical Biomarker Diagnostic Laboratory

MD Biosciences provides its biomarker expertise through its CLIA Clinical Diagnostics laboratory, one of the few largest independent, regional, clinical laboratories in the upper midwest of the United States. Services include biomarker validation and assay development as well as proprietary cancer markers, specifically in the area of gastro-intestinal carcinomas. Services are rounded out with routine clinical chemistry, urinalysis and hematology analyses provided with same day turn-around of samples. Learn more about the services and what our laboratory can do for your studies and samples.

Discover

MD Biosciences Research Products

MD Biosciences develops monoclonal antibodies, proteins and assays through the course of its research. Such products are manufactured and provided for sale through our dedicated offices and representatives throughout the world. Discover our products including the ArthritoMAB® antibody cocktail for induction of arthritis, our bovine collagen products, Neurofreeze® for the preservation of neuronal cells, our unique anti-mouse IgD for the study of B-cell activation and many other exciting products.

Discover

Collaborative Drug Development

Learn about our emerging pipeline of lead compounds addressing unmet needs at the cross-section of inflammation and pain. Our pipeline includes lead, first-in-class, non-opioid compounds for the therapy of neuropathic and chronic pain as well as vectorized vaccine for canine osteosarcoma with its equivalent in development for human therapeutic applications. Collaborative activity is supported by InnovX®, the platform for taking nascent technologies from bench to lead status. Talk to us about our collaboration and investment possibilities.

Discover

Have Questions? Contact Us

LATEST NEWS

MD Biosciences to Present At 13th Int'l Neuroimmunology Congress

Sep 6, 2016 4:55:34 PM

St. Paul, Minn., September 6, 2016 - MD Biosciences announces its attendance at the 13th ... Read More

Preclinical Study | Microbiome Effects | Metastatic Tumor Progression

Jul 1, 2016 4:44:55 PM

4th Annual Immuno-Oncology Summit, Boston, MA St. Paul, Minn., July 1, 2016 - MD ... Read More

Upcoming Event

13th Intl. Congress on Neuro-Immunology

SEPT 26-29, 2016

JERUSALEM, ISRAEL

Poster Presentation: The function of pain associated fibers in MOG induced EAE